R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose: The type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the pathogenesis of the Ewing sarcoma family of tumors (ESFT). We conducted a multicenter phase II study of the fully human IGF-1R monoclonal antibody R1507 in patients with recurrent or refractory ESFT. Patients and Methods: Patients ≥ 2 years of age with refractory or recurrent ESFT received R1507 at doses of 9 mg/kg intravenously one a week or 27 mg/kg intravenously every three weeks. Response was measured by using WHO criteria. Tumor imaging was performed every 6 weeks for 24 weeks and then every 12 weeks. Results: From December 2007 through April 2010, 115 eligible patients from 31 different institutions were enrolled. The median age was 25 years (range, 8 to 78 years). The location of the primary tumor was bone in 57% of patients and extraskeletal in 43% of patients. A total of 109 patients were treated with R1507 9 mg/kg/wk, and six patients were treated with 27 mg/kg/3 wk. The overall complete response/partial response rate was 10% (95% CI, 4.9% to 16.5%). The median duration of response was 29 weeks (range, 12 to 94 weeks), and the median overall survival was 7.6 months (95% CI, 6 to 9.7 months). Ten of 11 responses were observed in patients who presented with primary bone tumors (P = .016). The most common adverse events of grades 3 to 4 were pain (15%), anemia (8%), thrombocytopenia (7%), and asthenia (5%). Conclusion: R1507 was a well-tolerated agent that had meaningful and durable benefit in a subgroup of patients with ESFT. The identification of markers that are predictive of a benefit is necessary to fully capitalize on this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Molecular and Cellular Aspects of the Insulin-Like Growth Factor I Receptor
LEROITH, D., WERNER, H., BEITNER-JOHNSON, D., & ROBERTS, A. T. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-2-143 · Cited by 1,423
Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J. H., Pritchard, D. J., Gebhardt, M. C., Dickman, P. S., Perlman, E. J., Meyers, P. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020890 · Cited by 1,328
Self-citationBalamuth, N. J., & Womer, R. B. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70286-4 · Cited by 686
Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., Batzel, G. N., Yin, D., Pritchard-Jones, K., Judson, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70354-7 · Cited by 340
Self-citationGranowetter, L., Womer, R., Devidas, M., Krailo, M., Wang, C., Bernstein, M., Marina, N., Leavey, P., Gebhardt, M., Healey, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1478 · Cited by 330
Tolcher, A. W., Sarantopoulos, J., Patnaik, A., Papadopoulos, K., Lin, C.-C., Rodon, J., Murphy, B., Roth, B., McCaffery, I., Gorski, K. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6745 · Cited by 308
Baselga, J. M., Tripathy, D., Mendelsohn, J., Baughman, S. A., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J. L., et al. (1999) · PubMed · Cited by 300
The Insulin-like Growth Factor-I Receptor Is Required for EWS/FLI-1 Transformation of Fibroblasts
Toretsky, J. A., Kalebic, T., Blakesley, V., LeRoith, D., & Helman, L. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.49.30822 · Cited by 250
Self-citationKurzrock, R., Patnaik, A., Aisner, J., Warren, T., Leong, S., Benjamin, R., Eckhardt, S. G., Eid, J. E., Greig, G., Habben, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3220 · Cited by 196
Self-citationScotlandi, K., Benini, S., Nanni, P., Lollini, P., Nicoletti, G., Landuzzi, L., Serra, M., Manara, M. C., Picci, P., & Baldini, N. (1998) · PubMed · Cited by 185
IGF-I mediated survival pathways in normal and malignant cells
Kurmasheva, R. T., & Houghton, P. J. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.05.003 · Cited by 178
Planned versus attained design in phase II clinical trials
Green, S. J., & Dahlberg, S. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110703 · Cited by 178
Long-term Survivors of Childhood Ewing Sarcoma: Report From the Childhood Cancer Survivor Study
Ginsberg, J. P., Goodman, P., Leisenring, W., Ness, K. K., Meyers, P. A., Wolden, S. L., Smith, S. M., Stovall, M., Hammond, S., Robison, L. L., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq278 · Cited by 171
Self-citationHuang, F., Greer, A., Hurlburt, W., Han, X., Hafezi, R., Wittenberg, G. M., Reeves, K., Chen, J., Robinson, D., Li, A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0835 · Cited by 164
Self-citationCao, L., Yu, Y., Darko, I., Currier, D. G., Mayeenuddin, L. H., Wan, X., Khanna, C., & Helman, L. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1712 · Cited by 148
Self-citationBenini, S., Manara, M. C., Baldini, N., Cerisano, V., Serra, M., Mercuri, M., Lollini, P., Nanni, P., Picci, P., & Scotlandi, K. (2001) · PubMed · Cited by 141
The Role of IGF-1R in Pediatric Malignancies
Kim, S. Y., Toretsky, J. A., Scher, D., & Helman, L. J. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0189 · Cited by 92
Self-citationZha, J., O'Brien, C. L., Savage, H. M., Huw, L., Zhong, F., Berry, L., Phillips, G. D. L., Luis, E., Cavet, G., Hu, X., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0381 · Cited by 86
Loss of imprinting of IGF2 in Ewing's sarcoma.
Zhan, S., Shapiro, D. N., & Helman, L. J. (1995) · PubMed · Cited by 59
Self-citationTargeting IGF-1R in the treatment of sarcomas: past, present and future
Kim, S. Y., Wan, X., & Helman, L. J. (2009) · Bulletin du Cancer · doi:10.1684/bdc.2009.0915 · Cited by 19
Self-citation
Cited by
Teprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hogendoorn, P. C. W., Athanasou, N., Bielack, S., De Alava, E., Dei Tos, A. P., Ferrari, S., Gelderblom, H., Grimer, R., Sundby Hall, K., Hassan, B., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq223 · Cited by 718
Advances in sarcoma genomics and new therapeutic targets
Taylor, B. S., Barretina, J., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3087 · Cited by 427
Self-citationRiggi, N., Suvà, M. L., & Stamenkovic, I. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2028910 · Cited by 344
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., Rose, P. S., Folpe, A. L., & Laack, N. N. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.01.015 · Cited by 298
Metadata
- Authors
- Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K.-P., Chawla, S. P., Toner, G. C., Maki, R. G., Meyers, P. A., Chugh, R., Ganjoo, K. N., Schuetze, S. M., Juergens, H., Leahy, M. G., Geoerger, B., Benjamin, R. S., Helman, L. J., & Baker, L. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-12-01
- Volume
- 29
- Issue
- 34
- Pages
- 4541-4547
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2044313879
- Cited by
- 322
- References
- 24
- FWCI
- 29.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.